150 related articles for article (PubMed ID: 24626777)
1. Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.
Barboro P; Salvi S; Rubagotti A; Boccardo S; Spina B; Truini M; Carmignani G; Introini C; Ferrari N; Boccardo F; Balbi C
Int J Oncol; 2014 May; 44(5):1589-98. PubMed ID: 24626777
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells.
Barboro P; Borzì L; Repaci E; Ferrari N; Balbi C
PLoS One; 2013; 8(11):e79212. PubMed ID: 24236111
[TBL] [Abstract][Full Text] [Related]
3. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer.
Barboro P; Repaci E; Rubagotti A; Salvi S; Boccardo S; Spina B; Truini M; Introini C; Puppo P; Ferrari N; Carmignani G; Boccardo F; Balbi C
Br J Cancer; 2009 May; 100(10):1608-16. PubMed ID: 19401687
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.
Barboro P; Repaci E; Ferrari N; Rubagotti A; Boccardo F; Balbi C
Prostate; 2011 Sep; 71(13):1466-79. PubMed ID: 21321982
[TBL] [Abstract][Full Text] [Related]
6. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation.
Mukhopadhyay NK; Kim J; Cinar B; Ramachandran A; Hager MH; Di Vizio D; Adam RM; Rubin MA; Raychaudhuri P; De Benedetti A; Freeman MR
Cancer Res; 2009 Mar; 69(6):2210-8. PubMed ID: 19258514
[TBL] [Abstract][Full Text] [Related]
8. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
Zhao H; Coram MA; Nolley R; Reese SW; Young SR; Peehl DM
J Urol; 2012 Dec; 188(6):2158-64. PubMed ID: 23088973
[TBL] [Abstract][Full Text] [Related]
9. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma.
Chen LC; Hsueh C; Tsang NM; Liang Y; Chang KP; Hao SP; Yu JS; Chang YS
Clin Cancer Res; 2008 Jun; 14(12):3807-13. PubMed ID: 18559600
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.
Barboro P; Ferrari N; Balbi C
Cancer Lett; 2014 Oct; 352(2):152-9. PubMed ID: 25016060
[TBL] [Abstract][Full Text] [Related]
13. [Vinculin and the androgen receptor in prostate cancer: expressions and correlations].
Zhu LY; Zhong KB; Lu SX; He LY
Zhonghua Nan Ke Xue; 2010 Sep; 16(9):794-8. PubMed ID: 21171262
[TBL] [Abstract][Full Text] [Related]
14. Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54.
Yang Z; Chang YJ; Miyamoto H; Yeh S; Yao JL; di Sant'Agnese PA; Tsai MY; Chang C
Endocrinology; 2007 Mar; 148(3):1340-9. PubMed ID: 17110431
[TBL] [Abstract][Full Text] [Related]
15. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
16. PYK2 via S6K1 regulates the function of androgen receptors and the growth of prostate cancer cells.
Hsiao YH; Huang YT; Hung CY; Kuo TC; Luo FJ; Yuan TC
Endocr Relat Cancer; 2016 Aug; 23(8):651-63. PubMed ID: 27492635
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
18. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma.
Wu CS; Chang KP; Chen LC; Chen CC; Liang Y; Hseuh C; Chang YS
Oral Oncol; 2012 Jun; 48(6):516-22. PubMed ID: 22321252
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.
Ko YJ; Devi GR; London CA; Kayas A; Reddy MT; Iversen PL; Bubley GJ; Balk SP
J Urol; 2004 Sep; 172(3):1140-4. PubMed ID: 15311058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
